@FiercePharma: Merck has the Zilmax PR right: Animal advocate Temple Grandin to consult on livestock drug's safety. More | Follow @FiercePharma
@EricPFierce: Regeneron takes a "byte" out of excess manufacturing capacity in Ireland. ICYMI yesterday | Follow @EricPFierce
@CarlyHFierce: Amid Purdue criticism, CVS cuts opioid access for 'risky' prescribers. ICYMI yesterday | Follow @CarlyHFierce
> Germany's Fresenius said today that it is addressing issues raised by the FDA in a warning letter about a blood bag manufacturing facility in Puerto Rico. Report
> A new study says the market for drugs to treat dyslipidemia will reach $31 billion in 2022 and that statins will remain the biggest sellers, despite work on new treatments. Story
> SBI Pharmaceuticals is striking a deal in Bahrain to open a manufacturing facility to produce diabetes and cancer drugs. Report
> The FDA is looking more closely at the accuracy of consumer blood glucose testing. Report (reg. req.)
> Lupin has gotten FDA approval to make a generic of Sanofi's ($SNY) tuberculosis drug Rifadin. Item
@FierceMedDev: Bard settles vaginal mesh suit as thousands pend. ICYMI yesterday | Follow @FierceMedDev
@DamianFierce: Israel's InSightec is expanding into Canada with its surgery-free uterine fibroid treatment. News | Follow @DamianFierce
@MarkHFierce: We're launching a new diagnostics report in less than a week, and I'll be writing it. Sign up here | Follow @MarkHFierce
@MichaelGFierce: FDA clears Novo Nordisk's insulin injection pen for children. Item | Follow @MichaelGFierce
> FDA's guidance for wireless devices sparks business opportunity. More
> KKR, Bain said to bid for Panasonic's billion-dollar health unit. Article
> A first: Medtronic co-founder absent from annual meeting. Item
Biotech News
@FierceBiotech: Shire and Santaris extend their strategic alliance to discover, develop LNA-drugs in the rare disease field. Press release | Follow @FierceBiotech
@JohnCFierce: The latest on the Onyx buyout: Yes they are. No they aren't. Say what? Item | Follow @JohnCFierce
@EmilyMFierce: This week's career moves in biopharma. Chutes & Ladders | Follow @EmilyMFierce
> GlaxoSmithKline ponders future of Crohn's disease drug after PhIII flop. Report
> 3-D printing creates living tissue cells, holds promise for medical research. Story
> Vical restructures, chops 47 jobs after PhIII immunotherapy flop. Article
> Mystery doc cited for handing insider trial info to SAC trader. Report
And Finally... Procter & Gamble ($PG), which has a significant OTC joint venture with Teva Pharmaceutical Industries ($TEVA), today acknowledged paying a $3.3 million bonus in 2013 to former CEO Bob McDonald, who stepped down in May amid disappointing sales by the company. Report